ST八菱(002592) - 2024 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2024 is projected to be between 56 million and 84 million CNY, representing a decrease of 20.38% to 46.92% compared to the previous year's profit of 105.5 million CNY[3] - The net profit after deducting non-recurring gains is expected to be between 50 million and 75 million CNY, indicating a growth of 53.12% to 129.69% from last year's figure of 32.65 million CNY[3] - The basic earnings per share are forecasted to be between 0.20 CNY and 0.31 CNY, down from 0.40 CNY in the previous year[3] Factors Influencing Profit - The decline in net profit is primarily attributed to the absence of non-recurring gains from the sale of a 15% stake in Beijing Hongrun Tianyuan Gene Biotechnology Co., which generated a one-time investment income of 69.02 million CNY in 2023[6] - The increase in net profit after excluding non-recurring items is driven by higher revenue from new products and a reduction in share-based payment expenses[6] Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report[7]